---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-005341"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:30:39.992140+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics announces dismissal of securities class action lawsuit against all defendants

## Summary
- Securities class action filed Sept 13, 2024, alleging false statements on Dovitinib NDA prospects dismissed with prejudice.
- No settlement or payment was made by the Company or officers in connection with dismissal.
- CEO Thomas Jensen says dismissal allows focus on Phase 2 trial of stenoparib for advanced ovarian cancer.

## SEC filing metadata
- accession: 0001437749-25-005341
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925005341/0001437749-25-005341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925005341/allr20250226_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-005341
- JSON: https://secwatch.observer/filing/0001437749-25-005341.json
- Plain text: https://secwatch.observer/filing/0001437749-25-005341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.